Jeroen van de Pol

178 Chapter 6 Institute change Instituting change in this regard means normalizing CPS in daily practice [96] and preventing acceleration from diminishing over time. This is a joint responsibility of professional bodies and other stakeholders: 1. Professional bodies should adopt change within professional guidelines a. Continuous development of pre- and postgraduate training both for pharmacists and pharmacy technicians b. Development of quality indicators 2. Policy makers and regulatory bodies should adopt change within rules and regulation 3. Healthcare insurance companies should adopt community pharmacist reimbursement schemes focusing on CPS Regarding the first point, the amount and quality of CPS provision is determined early in education and training. Therefore, this point should focus predominantly on topics that are considered desirable during community pharmacists’ professional careers. However, demand and preferences from patients and other healthcare providers can shift over time, so education and training needs to be continuously developed to align with these preferences and demands. Furthermore, the professional body determines the content and desired quality of services that all community pharmacies should provide, including CPS. This determination is achieved by developing professional guidelines. Some aspects of CPS are already described in these guidelines. However, additional services that have been implemented in daily community pharmacy practice should also be described. By doing so, the Royal Dutch Pharmacists Association can continuously move the profession forward. Progress is accomplished by first supporting the development and implementation of CPS and, when CPS has become normalized, adopting it into professional guidelines and developing quality indicators to turn it into a minimum requirement. Community pharmacists who fully comply with these professional guidelines may be provided with certification, so they can present this certification to patients, other healthcare providers, regulatory bodies, and healthcare insurance companies. In addition, community pharmacists who do not adhere to these professional guidelines should be held accountable. With regard to the second point, stakeholders outside the community pharmacy profession, such as regulatory bodies and healthcare insurance companies, should create the conditions needed for community pharmacists to adhere to these newly developed professional guidelines. The Dutch Healthcare Authority